切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2021, Vol. 15 ›› Issue (06) : 463 -466. doi: 10.3877/cma.j.issn.1674-3253.2021.06.003

临床研究

尿液前列腺癌基因（PCA3）联合多参数磁共振对前列腺癌的诊断价值
张可1, 蒋伟1, 黎卓君1, 毛伟斌1, 张悦1, 孟占鳌1,†()   
  1. 1. 510630　广州，中山大学附属第三医院放射科
  • 收稿日期:2021-08-30 出版日期:2021-12-01
  • 通信作者: 孟占鳌
  • 基金资助:
    广东省科技计划项目(2016A020215073); 广东省自然科学基金项目(2017A030313478); 广州市科技计划项目(201804010324)

A pilot study on urinary PCA3 combined with multiparametric MRI for the diagnosis of prostate cancer

Ke Zhang1, Wei Jiang1, Zhuojun Li1, Weibin Mao1, Yue Zhang1, Zhan'ao Meng1,†()   

  1. 1. Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
  • Received:2021-08-30 Published:2021-12-01
  • Corresponding author: Zhan'ao Meng
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张可, 蒋伟, 黎卓君, 毛伟斌, 张悦, 孟占鳌. 尿液前列腺癌基因（PCA3）联合多参数磁共振对前列腺癌的诊断价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(06): 463-466.

Ke Zhang, Wei Jiang, Zhuojun Li, Weibin Mao, Yue Zhang, Zhan'ao Meng. A pilot study on urinary PCA3 combined with multiparametric MRI for the diagnosis of prostate cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2021, 15(06): 463-466.

目的

探讨尿液前列腺癌基因3（PCA3）联合多参数磁共振（mpMRI）对前列腺癌的诊断价值。

方法

以前列腺活检病理结果为金标准，选取40例前列腺癌患者和28例前列腺增生患者为研究对象，采用RT-PCR检测尿液PCA3表达水平，应用受试者操作特性（ROC）曲线分析尿液PCA3、mpMRI及两者联合对前列腺癌的诊断效能。

结果

前列腺癌组和前列腺增生组尿液PCA3表达量分别为（6.25±1.21）copies/ml和（2.26±0.95）copies/ml（P<0.001）；尿液PCA3、mMRI及两者联合诊断前列腺癌的曲线下面积分别为0.693（95%CI：0.569~0.799），0.720（95%CI：0.598~0.822）和0.830（95%CI：0.719~0.910）。

结论

尿液PCA3联合mMRI对前列腺癌诊断具有较好的临床价值。

关键词: 前列腺癌, 诊断, PCA3, 多参数磁共振
Objective

To investigate the diagnostic value of urinary prostate cancer gene 3 (PCA3) combined with multiparametric MRI (mpMRI) in prostate cancer.

Methods

RT-PCR was used to detect the expression level of urinary PCA3 of 40 patients with prostate cancer and 28 patients with benign prostatic hyperplasia. The receiver operating characteristic (ROC) curves was constructed to analyze the sensitivity and specificity of urinary PCA3, mpMRI and the combination of them for the diagnosis of prostate cancer.

Results

The expression level of urinary PCA3 in benign prostatic hyperplasia was lower than that in prostate cancer [(2.26±0.95) copies/ml vs (6.25±1.21) copies/ml, P<0.001]. The area under ROC for PCA3, mpMRI, and the combination were 0.693 (95%CI: 0.569-0.799), 0.720 (95%CI: 0.598-0.822), and 0.830 (95%CI: 0.719-0.910), respectively.

Conclusions

The determination of urinary PCA3 combined with mpMRI was valuable biomarker for the diagnosis of prostate cancer.

Key words: Prostate cancer, Diagnosis, prostate cancer gene 3, multiparametric MRI
表1 两组入组患者的一般情况的比较
组别 例数 年龄[岁，(±s)] PCA3[分，(±s)] mpMRI PI-RADS V2评分(例) Gleason评分(例) 临床病理分期(例)
1~2 3 4~5 < 8 ≥8 T1~T2 T3~T4
前列腺增生 28 69±10 38.0±16.0 17 7 04 - - - -
前列腺癌 40 65±11 26.6±15.3 10 8 22 16 24 18 22
统计值   t=1.7 t=4.165 χ2=1.8 - -
P值   0.12 <0.001 0.38 - -
图1 尿液PCA3表达水平及诊断ROC曲线
图2 尿液PCA3、mpMRI及两者联合诊断前列腺癌的ROC曲线
[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2]
Wang R, Chinnaiyan AM, Dunn RL, et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care[J]. Cancer, 2009, 115(17): 3879-3886.
[3]
Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management ofprostate cancer[J]. Eur Urol, 2011, 59(6): 962-977.
[4]
Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy[J]. Clin Cancer Res, 2010, 16(6): 1875-1883.
[5]
Sciarra A, Panebianco V, Cattarino S, et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy[J]. BJU Int, 2012, 110(11): 1661-1665.
[6]
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging-reporting and data system: 2015, Version 2[J]. Eur Urol, 2016, 69(1): 16-40.
[7]
Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis[J]. Asian J Androl, 2014, 16(3): 487-92.
[8]
Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis[J]. Sci Rep, 2016, 6: 25776.
[9]
Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate specific antigen levels[J]. BJU Int, 2009, 104(6): 730-733.
[10]
Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection[J]. BJU Int, 2011, 108 (8 Pt 2): E171-E178.
[11]
张其强, 赵云丽, 张学宝, 等. PCA3基因在前列腺癌的诊断和治疗中的研究进展[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(03): 207-210.

URL    
[12]
Yousaf T, Dervenoulas G, Politis M. Advances in MRI methodology[J]. Int Rev Neurobiol, 2018, 141: 31-76.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(11): 1089-1091.
[2] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[3] 祝炜安, 林华慧, 吴建杰, 黄炯煅, 吴婷婷, 赖文杰. RDM1通过CDK4促进前列腺癌细胞进展的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 618-625.
[4] 王功炜, 李书豪, 魏松, 吕博然, 胡成. 溶瘤病毒M1对不同前列腺癌细胞杀伤效果的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 626-632.
[5] 施一辉, 张平新, 朱勇, 杨德林. 机器人辅助前列腺根治术后切缘阳性的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 633-637.
[6] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断：AI离临床还有多远？[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[7] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[8] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[9] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[10] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号